LAB

Standard Biotools Inc
NASDAQHEALTHCAREMEDICAL DEVICES

Key Statistics

Market Cap
$339.87M
P/E Ratio
EPS
$-0.13
Beta
1.42
52W High
$1.72
52W Low
$0.70
50-Day MA
$0.95
200-Day MA
$1.17
Dividend Yield
Profit Margin
90.70%
Forward P/E
PEG Ratio

About Standard Biotools Inc

Standard Biotools Inc. (LAB) is a pioneering biotechnology company dedicated to enhancing genomic analysis and biological research through cutting-edge tools and technologies. The firm's focus on developing high-performance products for laboratories in genomics and proteomics is aimed at improving research precision and operational efficiency. Utilizing proprietary platforms, Standard Biotools accelerates scientific discoveries, reinforcing its position as a leader in the dynamic biotechnology landscape. With a commitment to meeting the growing demand for innovative analytical solutions, LAB is strategically positioned to facilitate significant advancements within the life sciences sector.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$86.25M
Gross Profit (TTM)$45.95M
EBITDA$-68.21M
Operating Margin-44.50%
Return on Equity-9.86%
Return on Assets-8.05%
Revenue/Share (TTM)$0.23
Book Value$1.44
Price-to-Book0.64
Price-to-Sales (TTM)3.93
EV/Revenue0.269
EV/EBITDA-19.22
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)4.60%
Shares Outstanding$391.46M
Float$209.46M
% Insiders1.69%
% Institutions76.63%

Historical Volatility

HV 10-Day
71.16%
HV 20-Day
71.80%
HV 30-Day
131.35%
HV 60-Day
99.31%
HV Rank
99.2%

Volatility is currently contracting

Analyst Ratings

Consensus ($1.55 target)
1
Buy
1
Hold

Latest News

LiveRamp Launches Agentic Partner Program to Fast-Track Agentic Deployments for Customers

SAN FRANCISCO--(BUSINESS WIRE)--LiveRamp (NYSE: RAMP), the leader in data collaboration, today announced LiveRamp Agent Builders (LAB), a new program to bring more partner-built agents into its network and accelerate marketers' ability to transform planning, measurement, activation, and data transformation with AI. During LAB's pilot period, brands will have access to agents from all of the AI companies participating in the program, enabling customers to focus on finding tools that create value.

Business Wire6/17/2026Neutral
Labrador Gold to Host Investor Webinar on the Mariposa Gold Project in Yukon's White Gold District

TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Labrador Gold Corp. (TSX Venture: LAB) ("Labrador Gold" or the "Company") is pleased to announce that it will host a live investor webinar on Wednesday, June 17, 2026, at 12:00 PM PT / 3:00 PM ET, featuring President and CEO Roger Moss and moderated by Cory Fleck of the KE Report. The webinar will provide investors with an in-depth overview of the Company's recently acquired Mariposa Gold Project, including its strategic location within the Yukon's prolific White Gold District, historical exploration results, the recently approved Class 1 permit, planned 2026 exploration activities and upcoming catalysts as the Company advances this district-scale gold opportunity.

GlobeNewsWire6/11/2026Neutral
Labrador Gold Announces 2026 Exploration Plans for Pacific Ridge's White Gold Projects

Vancouver, British Columbia--(Newsfile Corp. - June 11, 2026) - Pacific Ridge Exploration Ltd. (TSXV: PEX) (OTCQB: PEXZF) (FSE: PQW) ("Pacific Ridge" or the "Company") is pleased to report that Labrador Gold Corp. (TSXV: LAB) ("LabGold") has announced plans for its 2026 exploration programs for the Company's Mariposa and Eureka Dome gold projects in the White Gold District, Yukon.

Newsfile Corp6/11/2026Neutral

More HEALTHCARE Stocks

Data last updated: 7/9/2026